Comparative Pharmacology

Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 4 IN DEXTROSE 5 IN PLASTIC CONTAINER versus PARACAINE.

Peer-Reviewed Evidence

Differential Analysis

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER vs PARACAINE

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

Local Anesthetic / Antiarrhythmic (Class Ib)

Category A/B

PARACAINE

Local Anesthetic

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Lidocaine is a sodium channel blocker that inhibits depolarization of cardiac myocytes and nerve axons by binding to voltage-gated sodium channels and stabilizing the neuronal membrane, thereby preventing the propagation of action potentials.

Local anesthetic that reversibly blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction.

Clinical Dosing

Intravenous infusion: 1-4 mg/min (20-50 mcg/kg/min) for cardiac arrhythmias. Bolus: 1-1.5 mg/kg IV, then infusion.

10-20 mg orally every 4-6 hours as needed; maximum 80 mg/day.

Direct Interaction

None Documented

Half-Life

Terminal elimination half-life approximately 1.5-2 hours after bolus, prolonged to 2-4 hours in heart failure or hepatic impairment; continuous infusion may show context-sensitive half-life.

Other Significant Interactions

Clinical Note

moderate

Proparacaine + Fluticasone propionate

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate."

Clinical Note

moderate

Proparacaine + Clemastine

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine."

Clinical Note

moderate

Proparacaine + Venlafaxine

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine."

Clinical Note

moderate